Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.

Fluticasone, budesonide comparably effective for initial EoE treatment

15 Jul 2019

Fluticasone, swallowed from a multidose inhaler (MDI), and oral viscous budesonide (OVB) slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis (EoE), a recent study has found.

Researchers randomly assigned 129 patients with newly diagnosed EoE to receive 8 weeks of either 1 mg/4 mL OVB twice daily with a placebo inhaler (n=65; mean age, 36.2±19.1 years; 62 percent male) or 880 µg MDI twice daily with a placebo slurry (n=64; mean age, 39.0±14.5 years; 69 percent male). The post-treatment maximum eosinophil count per high-power field (eos/hpf) and validated dysphagia score were primary outcomes.

Peak eosinophil counts in the OVB arm dropped from 72.6±45.6 at baseline to 14.7±29.0 after 8 weeks. In the same time span, counts in the MDI group went from 76.9±62.3 to 20.9±34.3. There was no significant difference between groups in final eosinophil counts (p=0.31) and change from baseline (p=0.57).

A similar pattern was found for scores in the Dysphagia Symptom Questionnaire. In the OVB arm, mean scores dropped from 10.6±9.3 at baseline to 4.8±7.3 after 8 weeks, while results changed from 8.2±9.9 to 4.2±7.5 in the MDI group. Change values were comparable between groups (p=0.37).

Moreover, both the OVB and MDI interventions were well tolerated. The incidence rate of adverse events in the corresponding arms were 15 percent and 23 percent. Oesophageal candidiasis was the most common side effect, though all cases were asymptomatic.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.